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ABSTRACT 
 Alzheimer’s disease (AD) is the most common form of dementia. It is a 
progressive neurodegenerative disease that is characterized by the increased 
abundance of amyloid beta (Aβ) plaques, and neurofibrillary tangles composed of 
hyperphosphorylated tau. Only a handful of medications have been approved by the 
Food and Drug Administration (FDA) since AD's discovery more than 100 years ago. 
These drugs only treat the symptoms and are best prescribed during the early stages of 
the disease. In addition, the drugs do not restore the cognitive loss. It is critical to 
discover a novel drug to treat and prevent this disease. We have chosen to repurpose 
tolfenamic acid (TA), a drug approved in Europe and parts of Asia, as a treatment for 
taupathies. 
 Data from our lab have shown that C57BL/6 mice treated with TA have 
lowered amyloid precursor protein (APP) and Aβ levels (Adwan et al., 2011). Our lab 
found that treating APP transgenic mice (line R1.40) with TA led to improved 
cognitive function and working memory assessed by the Morris water maze and Y-
maze, respectively, and reductions in Aβ plaque burden (Subaiea et al., 2013; 2015). 
The lab has also shown that R1.40 mice treated with TA showed a reduction in total 
tau, phospho-tau (p- tau) Ser235, Thr181, and CDK5 levels (Adwan et al., 2014). Sp1 
is a common transcription factor of both APP and tau that regulates their gene 
expression. Thus, we examined the ability of TA to alter tau and its phosphorylation 
levels, and its effects in improving learning and memory profile in an htau transgenic 
mouse model. These transgenic mice are hemizygous for the htau gene expressing all 
six isoforms of the human microtubule associated protein tau (MAPT),and they are 
  
homozygous knockout for the murine tau. We administered mice a corn oil vehicle or 
TA at 5 or 50 mg/kg for 34 consecutive days. Memory and learning were assessed by 
MWM and Probe Trial I and II. 
 The protein was isolated from the cortices of the mice. Total tau,  p-tau Ser396 
and Thr231 protein levels were measured by Western blot. Administration of TA 
showed a decrease in protein levels of both 5 and 50 mg/kg treatment groups in 
contrast to the control group. Immunohistochemistry staining for p-tau Thr231 showed 
reduced p- tau present in the frontal cortex and striatum. In the MWM, the control 
group showed poor spatial learning and memory deficits that were attenuated in both 
the 5 and 50 mg/kg TA groups. In addition, both TA treatment groups showed 
improved memory retention in Probe Trial I and II compared to the control. These 
results show TA as a novel drug for AD as it lowered AD biomarker protein levels and 
improved cognitive function within the htau mouse model. 
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CHAPTER 1 
INTRODUCTION 
 Alzheimer’s disease (AD) affects over 5 million Americans and it is the sixth 
leading cause of death in the US (Alzheimer’s Association, 2015). It is a 
neurodegenerative disease and it is the most common form of dementia. Dementia is 
characterized by the progressive loss of memory and decline in everyday activities. 
Neurons become damaged in demented patients and eventually die, leading to changes 
in memory, decision making, and behavior. People with AD often have difficulty 
completing familiar tasks and remembering friends and family. Eventually, patients 
lose their independence and require family members or friends for care. In 2013, an 
estimated 15.5 million caregivers provided 17.7 billion hours of unpaid care to those 
with AD, a value estimated at $220 billion. Based on these numbers, the cost of care is 
expected to increase to $1.2 trillion in 50 years (Alzheimer’s Association, 2015).  
  Two pathophysiologic hallmarks of the disease are the excess amount of 
amyloid beta (Aβ) plaques from amyloid precursor protein (APP) and neurofibrillary 
tangles (NFTs) formed by hyperphosphorylated tau protein. Specificity protein 1 (Sp1) 
is a transcription factor associated with AD pathology and it is the common 
transcription factor for APP and tau. Tau is a microtubule- associated protein (MAPT) 
that binds to tubulin, promoting the assembly and stabilization of microtubules. 
Normally, tau is phosphorylated by the main kinases cyclin-dependent kinase 5 
(CDK5) and glycogen synthase kinase 3 beta (GSK-3β). When tau becomes 
hyperphosphorylated at phosphorylation sites, such as Threonine (Thr) 231 or Serine 
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(Ser) 396, it can no longer bind to the microtubules. As a result, tau begins to 
aggregate and first form paired helical filaments (PHF) and then NFT. 
 The biggest risk factor for developing AD is age (Vinters, 2014). Currently, 1 
in 9 Americans over the age of 65 have AD and 1 in 3 people over 85 have the disease 
(Alzheimer’s Association, 2015). The risk of developing AD is expected to increase at 
an alarming rate over the next 50 years. This is because of the longer life expectancy 
and aging baby- boomers will account for 51% of the people diagnosed with AD ages 
65 and older (Alzheimer's Association, 2015). Without a cure, the number of people 
diagnosed is expected to rise from 5 million to 16 million by 2050 (Alzheimer’s 
Association, 2015, Brookmeyer et al., 1998; Nelson et al., 2011). 
 The costs associated with creating a new drug are on average of one billion 
dollars, and require up to 12 years of research and development (Ng, 2011, PhRMA, 
2013). Each phase of drug development progresses with risk and has a failure rate of 
over 95% (Hartung, 2013). As a result, many compounds or drugs are left abandoned 
in the pipeline with the potential to be repurposed. Repurposing a drug involves 
studying a pre-existing compound or biologic that is currently in use to treat a disease 
and determining if it can be used for the treatment of another disease (Ng, 2011). 
Furthermore, it is useful to study a drug that has already been approved and released to 
the market. This is because of the pharmacokinetic (PK) and pharmacodynamic (PD) 
parameters that have been established, saving research investment. 
 Since the identification of AD more than 100 years ago no drug has 
successfully targeted the pathological features of AD to alleviate and restore memory 
and cognition. However, drugs are available to treat symptoms of the disease such as 
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cholinesterase inhibitors (e.g. donepezil) and N-methyl-D-asparate antagonists (e.g. 
memantine). Cholinesterase inhibitors prevent the breakdown of acetylcholine (Ach), 
a neurotransmitter involved in memory, learning, and thinking. Patients with AD have 
lower levels of Ach and thus it is believed to benefit someone with impaired memory 
(Fayed et al., 2011). Drugs such as donepezil (Aricept) are best prescribed during the 
early stages of AD. However, the approved drugs only delay the worsening of 
cognitive deficits for 6- 12 months on average and at least half of the patients do not 
respond to them (Alzheimer’s Association, 2015). In addition, the neuronal damage 
caused by the disease cannot be reversed by these drugs (Mancuso et al., 2014, 
Ozudogru et al., 2012). Another cholinesterase inhibitor (e.g. tacrine) is no longer 
prescribed because liver damage was a serious side effect (Qizilbash et al., 2000). 
Developing a safe drug that not only targets the symptoms but also reverses the 
cognitive deficits is a critical step in fighting AD. Instead of  emulating the currently 
approved FDA medications which cannot cure the disease, we propose the drug, 
tolfenamic acid (TA), possess a unique mechanism of action different from what exists 
on the market. 
 TA is a non-steroidal anti-inflammatory drug (NSAID) currently approved for 
the treatment of migraines and rheumatoid arthritis in Europe. TA has been available 
for over 35 years and the PK and PD parameters are well cited. Unlike many NSAIDs 
that may cause gastric irritation, TA is a well- tolerated and safe drug (Alhava, 1994; 
Eskerod, 1994; Hendel, 1994; Isomaki et al., 1984). In addition, long-term studies 
reported minimal or no adverse effects with TA in gastrointestinal histology, renal 
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function, and liver function (Khwanjai 2012; Sankpal 2013). This makes TA a 
superior candidate to repurpose for AD research. 
 The distinct mechanism of TA targets the transcription factor Sp1, a zinc- 
finger DNA binding protein. It preferentially binds to GC- rich promoter regions  and 
regulates the expression of housekeeping genes (Beishline and Azizkhan- Clifford, 
2014 and Li et al., 2004). Sp1 is also studied in cancer research for its regulation of 
genes involved with cell growth, differentiation, apoptosis (Li et al., 2004; Kaczynski 
and Urrutia, 2003; Tan and Khachigian 2009). It has been noted that high Sp1 levels 
correlates with decreased survival for cancer patients (Li et al., 2004). Multiple cancer 
studies have shown TA's ability to inhibit Sp1 levels (Abdelrahim et al., 2006; Basha 
et al., 2005, 2011; Colon, 2009; Eslin et al., 2013; Maliakhal et al., 2012; Sankpal et 
al., 2013). In fact, when compared to many of the available NSAIDs, TA was able to 
significantly decrease Sp1(Abdelrahim et al., 2006). This was a strong indicator to 
select TA as a novel mechanism for AD. 
 Sp1 co-activates the transcription of APP and tau (Christensen et al., 2004; 
Docagne et al., 2004, Heicklen-Klein and Ginzburg, 2000). As a result, we have 
chosen to study this drug as a modifier of an upstream target for AD. It was shown 
that TA crosses the blood brain barrier within mice brains (Subaiea et al., 2011). In a 
follow-up study, wild-type C57BL/6 mice were dosed with TA and it was found that 
the gene expression of APP was lowered and protein levels of Sp1, APP, and its 
product Aβ were reduced relative to controls (Adwan et al., 2011). 
 Next, the transgenic mouse line (R1.40), hemizygous for the human APP gene, 
and SH-SY5Y cell line were used to investigate TA. It was reported that Sp1, APP, 
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and Aβ were reduced in both models (Adwan et al., 2013). More evidence was 
provided by dosing the same mouse model with TA for 34 days and finding a decrease 
in Sp1 and APP protein levels and Aβ, while Sp1 mRNA remained unchanged 
(Subaiea et al., 2013). Moreover, cognitive deficits and memory were recovered in 
behavioral tests, including the Morris water maze (MWM) and Y-maze. 
 Since Sp1 regulates the gene expression of both APP and tau, further research 
on tau was performed. Dosing R1.40 mice with TA for 34 days showed that tau 
mRNA and protein levels were lowered (Adwan et al., 2014). In addition, levels of 
phospho- tau (p-tau) at sites Thr 181 and Ser 235 were reduced. Based on the evidence 
that TA reduces tau in a human APP mouse model, we chose a new tau transgenic 
mouse model (htau) to study the effects of TA and tau proposed in Figure 1. It was 
important to select a mouse model that contained the human tau gene with a non-
mutated promoter region. htau mice develop tau pathology slower when compared to 
some mouse models, which have accelerated tau accumulation and earlier impaired 
memory. This way, the human AD pathology is resembled more accurately. 
 To study whether TA is effective in treating htau mice, total tau, p-tau Thr231 
and Ser396 were analyzed by Western blot. In addition, the gene expression of tau was 
measured by quantitative polymerase chain reaction (qPCR). Finally, the MWM and 
Probe Trial I and II behavior studies were performed to assess improvement in 
cognitive function.
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CHAPTER 2 
MATERIALS AND METHODS 
Animal model 
 The htau mouse model, strain B6.Cg-Mapt
tm1(EGFP)Klt
 Tg(MAPT)8cPdav/J, was 
obtained from Jackson Laboratory (Bar Harbor, ME). The animals are hemizygous for 
the human tau gene, expressing all six isoforms of the human tau (3R and 4R). The 
transgene contains the coding sequence, intronic regions, and regulatory elements of 
the endogenous human promoter region and they are homozygous for the knock-out 
murine tau. These mice aggregate paired helical filaments made of insoluble tau as 
early as 2 months and hyperphosphorylated tau is detected at 3 months of age. 
Visuospatial and learning deficits occur as early as 6 months assessed by the MWM. 
Mice were bred in-house in the designated animal facility at the University of Rhode 
Island with a 12:12 hour light-dark cycle (light on at 6:00 AM; light off at 6:00 pm). 
Food and water were provided ad libitum. 
 
Genotyping of htau mice 
 Presence or absence of the human tau gene was determined through 
genotyping by standard polymerase chain reaction (PCR) using MJ Research 
MiniCycler PTC- 150 (Bio-Rad, Hercules, CA). Following the literature, DNA was 
isolated from 2 mm mouse tail snips (Turuett et al., 2000).  Tail snips were placed in 
an Eppendorf tube and 75 µl of 25 mM NaOH/ 0.2 mM EDTA was added and placed 
in a thermocycler at 98 
o
C for 1 h. After, the tail snips were mechanically ground with 
a pipette tip and then the temperature was reduced to 15 
o
C for 30 min. Next, 75 µl of 
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40 mM Tris HCl (pH 5.5) was added and centrifuged at 4,000 rpm for 3 min and 
supernatants were collected. DNA integrity was checked using NanoDrop 2000 
Micro- Volume UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE). 
 All the following reagents in this section were obtained from Invitrogen 
(Carlsbad, CA), unless otherwise stated. Standard PCR was used with the following 
primers: sense 5'-CGAAGTGATGGAAGATCACG-3' and antisense 5'-
GTCTTGGTGCATGGTGTAGC-3'. Each reaction consisted of 44 µl Platinum PCR 
SuperMix, 2 µl of each primer, 1 µl 10X BlueJuice loading dye, and 1 µl DNA with 
the reaction cycle as follows: 95 
o
C for 2 min, 95 
o
C for 30 s, 50 
o
C for 30 s, and 72 
o
C 
for 15 s for 35 cycles. Next, bands were separated on a 2% UltraPure agarose gel 
containing ethidium bromide by gel electrophoresis and imaged using Typhoon™ 
9410 Variable Mode Imager (GE Healthcare, Piscataway, NJ). 
 
Mice exposure to tolfenamic acid (TA) 
 The previous mouse model used by the lab (APP YAC, line R1.40) showed 
TA affected the amyloid and tau pathology. Our lab has shown that TA has the ability 
to decrease levels of APP, Aβ, tau, CDK5, β- APP cleaving enzyme 1 (BACE1), and 
Sp1 in this mouse model (Adwan et al., 2014; Subaeia et al., 2011, 2013, 2015). In 
addition, we have shown that  memory and cognitive function were attenuated in these 
mice by administering TA. 
 TA was obtained from Sigma- Aldrich (St. Louis, MO). Since tau begins to 
aggregate at 3 months, male and female htau mice from different cohorts, aged 3-4 
and 5-8 months, were used to examine TA's ability to lower tau pathology. Each 
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cohort was separated into 4 groups by similar age variation and gender and dosed with 
TA or corn oil vehicle by oral gavage for 34 consecutive days. On Day 15 of dosing, 
behavior studies began and concluded on Day 35 where mice were sacrificed and 
brain tissues were collected and stored at -80 
o
C until further use. Mice (aged 3-4 
months) were divided into two control groups as carrier of the human tau  (n= 10) and 
non-carrier of the human tau (n= 10). The third and fourth groups were given TA at a 
low dose of 5 mg/kg (n= 9) or high dose of 50 mg/kg (n= 10). Mice (aged 5-8 months) 
followed the same dosing scenario by oral gavage: control carrier (n= 5), control non-
carrier (n= 12), and TA at 5 mg/kg (n= 8) or 50 mg/kg (n= 7) The timeline of behavior 
studies are shown in Figure 2. Female mice (aged 13 months) were also dosed with 0 
(n= 3), 5 mg/kg (n= 3), or 50 mg/kg (n= 4) TA for 34 days for immunohistochemistry. 
All experiments were performed in accordance with the standard guidelines and 
protocol approved by the University of Rhode Island Institutional Animal Care and 
Use Committee with supervision of the university's veterinarian. 
 
Morris water maze 
 In the hidden version of the MWM, mice had to locate the hidden platform by 
learning multiple spatial cues by associating the platform location with the distal 
extramaze cues (Gulinello et al., 2009; Laczo et al., 2009; Vorhees and Williams, 
2006). The maze apparatus consisted of a white pool (48" diameter, 30" height) filled 
with water to a depth of 14". White, non-toxic paint (Crayola, New York City, NY) 
was used to make the water opaque. Distinct visual cues were placed along the sides 
of the pool for the animals to navigate to the escape platform. A clear Plexiglas 
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platform 10 cm
2
 was submerged 0.5 cm below the surface of the water and 
temperature of the water was maintained at 25 + 2 
o
C during all procedures. 
 A habituation trial allowed the mice to swim freely for 60 s to acclimate to the 
experiment, which commenced on Day 15 of drug administration. Mice received 3 
daily training sessions for a total of 8 days. The starting position was randomly 
assigned between four possible positions while the platform remained fixed for each 
trial.  Each animal had a maximum duration of 60 s to swim to find the immersed, 
hidden platform. If a mouse failed to locate the platform, it would be guided to sit on 
the platform for 30 s. If a mouse was successful, it could sit on the platform for a 
maximum of 10 s. Following the completion of 8 training day sessions, probe trials 
were performed up to 60 s on Day 24 and Day 34 to assess long-term memory 
retention and the mice's preference for the correct quadrant where the hidden platform 
was previously located. The swim paths and latencies were videotaped and analyzed 
with a computerized video- tracking system (ObjectScan, Clever Sys. Inc., Reston, 
VA, USA). 
 
Protein extraction and Western blot analyses 
 Brain cortices were homogenized with radio-immunoprecipitation assay 
(RIPA) lysis buffer (10 mM Tris- HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, 
0.1% sodium dodecyl sulfate, 1 mM ethylenediaminetetraacetic acid, 0.1% protease 
inhibitor cocktail, and 10 µl phosphatase inhibitor (Sigma- Aldrich). The homogenates 
were centrifuged at 8,000 rpm for 10 min at 4 
o
C and supernatants were collected. 
Protein concentration was determined by Pierce bicinchroninic assay (BCA) kit 
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(Thermo Scientific, Waltham, MA). Twenty- forty microgram of total protein were 
separated onto 10- 12% polyacrylamide gel at 100 V for 2 hours and then transferred 
to polyvinylidiene difluoride (PVDF) membranes (GE- Healthcare). Membranes were 
blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline containing 
0.5% Tween-20 (TBST) for 1 hour. Membranes were incubated with appropriate 
dilution of specific antibody in TBST overnight at 4 
o
C. The following antibodies 
were used: 1: 5,000 dilution of total tau  (ab32057, Abcam, Cambridge, MA); 1: 500 
Ser396 (PHF13) (9632, Cell Signaling, Beverly, MA); 1: 500 Thr231 (710126, 
Thermo Scientific); 1: 1000 GAPDH (Sigma-Aldrich). Membranes were washed with 
TBST 3 times and then incubated with the respective anti-mouse or anti-rabbit IRDye 
680 (Li-Cor, Lincoln, NE) at dilution 1: 5,000- 10,000 for 1 h at room temperature. 
After washing the membranes with TBST 3 times and TBS 2 times, images were taken 
with Odyssey Infrared Imaging System (Li-Cor). Membranes were reprobed for 
GAPDH to obtain protein/GAPDH ratio. The intensities of the Western blot bands 
were obtained using Odyssey V1.2 Software (Li-Cor). 
 
RNA isolation, cDNA synthesis, and quantitative real-time PCR 
 RNA was isolated from cortical tissue following the TRIzol Reagent method 
(Invitrogen), checked for integrity using NanoDrop 2000 Micro-Volume UV-Vis 
Spectrophotometer (Thermo Scientific) and reverse transcribed to cDNA using iScript 
Select cDNA Synthesis Kit using the manufacturer's instructions (Bio-Rad). About 
1000 ng of RNA was diluted to 20 µl with nuclease-free water, 4 µl 5x iScript select 
reaction mix, and 1 µl of reverse transcriptase added. Samples were incubated at 42 
o
C 
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for 90 min and then at 85 
o
C for 5 min to terminate the reaction. All incubations were 
conducted using MJ Research MiniCycler PTC- 150 (Bio-Rad). Primer pairs for 
human tau and GAPDH were obtained from Invitrogen as follows: tau (exon 2- 3) 
sense 5'-TGAACCAGGATGGCTGAGC-3' and antisense 5'-
TTGTCATCGCTTCCAGTCCRT-3' and GAPDH sense 5'-
AGGTCGGTGTGAACGGATTTG-3' and antisense 5'-
TGTAGACCATGTAGTTGAGGTCA-3'. Each real-time PCR reaction mix contained 
1 µl cDNA, 0.5 µl of each sense and antisense primer, 4.25 µl nuclease-free water, and 
6.25 µl SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) 
following the standard protocol: 50 
o
C for 2 min followed by 95 
o
C for 10 min then 40 
cycles of 95 
o
C for 15 sec and 60 
o
C for 1 min. The reaction was performed and 
analyzed using ViiA7 RUO Software (Applied Biosystems) and expression data were 
reported relative to GAPDH mRNA using the 2-
∆∆Ct 
method. 
 
Perfusion Preparation and Immunohistochemistry 
 After 34 days of TA treatment, htau mice (aged 13 months) were prepared for 
immunohistochemistry on Day 35.  Mice were deeply anesthetized with an 
intraperitoneal injection of 0.1 ml/10 g of xylazine- ketamine mixture (100 mg/ml- 10 
mg/ml) and perfused transcardially with 100 ml of perfusion wash consisting of 0.8% 
sodium chloride, 0.8% sucrose, 0.4% dextrose, 0.034% anhydrous sodium cacodylate, 
and 0.023% calcium chloride. After that, mice were perfused with 100 ml of perfusion 
fix that consisted of 4% paraformaldehyde, 4% sucrose, and 1.07% anhydrous sodium 
cacodylate (pH 7.2- 7.4), and their brains were removed. The extracted brains were 
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post-fixed in the perfusion fix solution overnight and then they were cryopreserved in 
30% sucrose solution. Fixed brains were sent to NeuroScience Associates (Knoxville, 
TN) for staining and coronal sectioning for p-tau Thr231 at a dilution of 1: 2,500. The 
frontal cortex and striatum were sectioned and the cell bodies and apical dendrites and 
axon tracts were stained, respectively. 
 
Statistical Analysis 
 Data were represented as the mean + standard error of the mean (SEM). 
Assessment of performance in MWM daily training sessions was determined using 
one-way ANOVA with Tukey-Kramer multiple comparison post-test, using GraphPad 
InStat 3 software (GraphPad Software, La Jolla, CA). Statistical analysis of western 
blot bands was determined by one-way ANOVA and Holm- Sidak comparisons with 
SigmaStat 3.5 software (Systat Software, Inc., San Jose, CA). Results with a p-value 
of  <0.05 were considered statistically significant and were marked with asterisks 
accordingly.
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CHAPTER 3 
RESULTS 
 Body weight was monitored during the study with no significant change and 
no overt toxic effects of TA administration were observed when compared to the non-
treated mice (Table 1). Standard PCR determined which mice contained the human tau 
transgene (Fig. 3). The presence of a band distinguished which mice were carriers of 
the human tau gene and which mice were non-carriers of the gene. In addition, 
Western blot confirmed that the carriers contained the human tau gene, shown by p-
tau Ser396, while the non-carriers were absent of the band (Fig. 4). GAPDH was re-
probed on the same membrane to confirm the presence of the protein. The effects of 
TA on tau are reported below. 
 
Evaluation of cognitive function in htau mice 
 Visuospatial and learning memories were assessed by the MWM in animals 
aged 3-4 months. To ensure carrier mice of the human tau gene were an appropriate 
control group with impaired memory at this age, they were compared to the non-
carrier htau mice. After the second day of training, the control carriers exhibited 
slower learning when compared to the control non-carrier group (Fig. 5). After Day 2, 
the non-carriers consistently had faster escape latencies between the two control 
groups. 
 
Administration of tolfenamic acid restores cognitive function in htau mice 
 It was previously shown that mice in the control carrier group have impaired 
cognitive function and memory deficit in the MWM. To further study if TA improves 
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the memory deficits in the behavior study, 5 and 50 mg/kg TA was administered to 
animals (aged 3-4 months). Over the training course of 8 days, both the memory in the 
5 and 50 mg/kg TA were attenuated with drug treatment when compared to the control 
group (Fig. 6). Both TA treatment groups had improved learning acquisition with 
faster escape latencies than the control carrier. The 5 mg/kg TA group had the fastest 
escape latency between the groups and learning memory was significantly improved in 
Days 3, 4, and 7, measured by one-way ANOVA (p < 0.05). In addition, probe trials, 
which assessed the percent time spent in the correct quadrant containing the hidden 
platform, demonstrated that the control carriers had learning deficits compared to the 
control non- carrier, 5 and 50 mg/kg TA in both Day 24 and Day 34 (Fig. 7). This 
further illustrated that not only do the non-carriers retain the long-term memory of the 
platform's location, but that animals dosed with TA recovered their cognitive function 
as shown by significantly spending more time in the correct quadrant with the hidden 
platform measured by one-way ANOVA (p < 0.05). 
 
Tolfenamic acid decreases tau protein levels and gene expression 
 Following 34 days of TA administration, total tau protein levels were 
significantly decreased in both the 5 and 50 mg/kg TA treated groups when compared 
to the control carriers as measured by Western blot (Fig. 8a). Tau protein levels were 
quantified as a ratio to housekeeping protein GAPDH (Fig. 8b).  Statistics was 
determined by one-way ANOVA (p = 0.032) and significance by Holm- Sidak post-
test (p < 0.05). In addition, tau gene expression was lowered with TA treatment. Tau 
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mRNA were reduced by 12% and 23% in the 5 and 50 mg/kg, respectively, compared 
to the control carriers (Fig. 9). 
 
Phosphorylated tau is lowered with tolfenamic acid treatment 
 Hyperphosphorylated tau loses its ability to bind and stabilize microtubules so 
levels of p-tau were examined with TA. p-tau Ser396 protein levels were lowered in 
both 5 and 50 mg/kg TA groups analyzed by Western blot (Fig. 10a). Band intensities 
were measured (Fig. 10b). Protein levels of p-tau Thr231 were also reduced after 
dosing with TA. Thr231 levels were decreased with drug treatment measured by 
Western blot (Fig. 11a). Thr231 protein was quantified with GAPDH levels and was 
reduced (Fig. 11b) as determined by one-way ANOVA (p =  0.007) with Holm- Sidak 
post-test (p < 0.05). 
 
Immunohistochemistry 
 As previously described, htau mice begin aggregating hyperphosphorylated tau 
at 3 months of age. After treating mice with 0, 5, and 50 mg/kg TA, mice (aged 13 
months) brains were sectioned and stained for p-tau Thr231 (Fig. 12; 5 mg/kg TA not 
shown). The frontal cortex showed decreased Thr231 staining in the cell bodies and 
dendrites with the TA treatment compared to the control group. Dosing with TA also 
reduced the Thr231 intensity staining of the axon tracts in the striatum. 
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CHAPTER 4 
DISCUSSION 
 TA is a novel drug for AD treatment. It has been used for the management of 
migraines and rheumatoid arthritis for over 35 years in Europe. This makes TA a well-
established and promising drug for repurposing in AD. Although the anti-
inflammatory benefits of NSAIDs have been studied in AD (Weggan et al., 2001; 
Wilkinson et al., 2012), it is TA's unique mechanism to chelate Sp1 that makes it an 
outstanding candidate for drug development in AD (Abdelrahim et al., 2006; Adwan 
et al., 2011; unpublished data). Many cancer studies have reported TA inhibition of 
Sp1 (Basha et al., 2006, 2011; Colon et al., 2011; Eslin et al., 2013; Maliakal et al., 
2012; Sankpal et al., 2012; Sutphin et al., 2014). Sp1 was shown to be elevated in the 
frontal cortex of AD brains and in the brains of AD mouse models (Citron et al., 2008; 
Santpere et al., 2006). Targeting this transcription factor is not likely to produce 
detrimental effects because Sp1 binds to CG-rich promoter regions which are present 
in <10% of genes (Levotsky and Dynan, 1989). In addition, Sp1 is essential during 
early embryonic development but not necessary for cell growth and differentiation 
later in life (Marin et al., 1997). Although TA can affect both APP and tau through 
Sp1, other studies suggest targeting tau may be more effective than the APP pathway. 
 The amyloid hypothesis has driven the development of many drugs that target 
the Aβ pathway and thus far, no drug has been successfully approved. For example, 
the hopeful anti-amyloid immunotherapy drugs, which use antibodies against Aβ (e.g. 
bapineuzumab and solanezumab) made it to Phase 3 clinical trials. However both 
drugs failed in that stage, showing no significant difference between the treatment 
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groups and control (Salloway et al., 2014). Semagacestat, a drug that inhibits the 
cleaving process of APP, has also failed in Phase 3. Moreover, 65.6% of drugs 
targeting the Aβ pathway from 2002- 2012 have failed, showing no efficacy against 
this target (Cummings et al., 2014). As a result, we have shifted our focus on tau since 
it is more associated with cognitive failure than Aβ (Medina, 2011; Terry et al., 1964; 
Thal et al., 2004). Reducing tau and Aβ levels did improve cognition in mouse models 
that express tangles and plaques; however, lowering Aβ alone did not improve 
cognitive function (Iqbal et al., 2009). Additionally, AD is the most common 
tauopathy and by focusing on tau, it may help treat other diseases. 
 Tauopathies are a class of over 20 neurodegenerative diseases characterized by 
hyperphosphorylated tau and impaired memory with no known cure (Brunden et al., 
2009; Lee et al., 2001; Santpere et al., 2006). Here, tau and cognitive deficits exist 
without the presence of Aβ (Iqbal et al., 2010). In fact, tau pathology is more 
corrolated with dementia in humans than β- amyloidosis (Terry et al., 1964; Thal et 
al., 2004). By targeting tau and the cognitive deficits associated with it, TA could be 
effective in such tauopathies like frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17), progressive supranuclear palsy, and Pick's disease. 
 TA's distinct mechanism of action is a promising, upstream intervention that is 
able to target tau and other AD pathological features. Furthermore, we have previously 
shown that administering TA in mice lowers Sp1 levels, reducing the subsequent AD 
biomarkers such as APP, Aβ, BACE1, CDK5, p-tau Ser235 and Thr181 (Adwan et al., 
2011, 2014; Subaeia 2013, 2015). p-tau Thr231 and Ser396 are almost fully 
phosphorylated in PHF tau (Morishima- Kawashima et al., 1995). In addition, Thr231 
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phosphorylation inhibits tau's microtubule-binding capability by 26% (Sengupta et al., 
1998). TA has the ability to decrease tau and its phosphorylated state as shown in 
Figure 8, 10, and 11. In the MWM, the low dose of 5 mg/kg TA showed better 
improvement in learning and memory compared to the 50 mg/kg TA. This reflects the 
human equivalent dose more accurately, where it is recommended to take a dose of 
200 mg, up to 3 times a day, during a migraine attack (EMEA, 1997). 
We have proposed a novel drug that can not only recover cognitive function in 
mice that contain the human tau gene, but also demonstrated that tau can be reduced in 
older mice with tau aggregation. The current AD drugs are not disease- modifying, as 
they only mask the symptoms and the memory is not attenuated. TA has the potential 
to treat AD by targeting crucial biomarkers involved in this neurodegenerative disease.
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Figure 1. Proposed mechanism of tolfenamic acid 
(TA) acting on transcription factor Sp1. TA prevents 
Sp1 from binding to the promoter region of the tau 
gene, reducing the amount of tau protein and potential 
NFT, resulting in lower AD pathology. 
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Figure 2. Timeline of dosing mice daily with TA for 34 days. Morris water 
maze (MWM) started on day 15 and continued for eight consecutive days. 
Following MWM conclusion, Probe Trial I was performed on Day 24 and 
Probe Trial II on Day 34, to assess long-term memory retention. Mice were 
sacrificed on Day 35 and tissues were collected. 
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Figure 3. Genotyping of htau mice analyzed by 
standard PCR. Bands represents human tau 
transgene while blank lanes represent mice 
without the human tau gene. 
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Figure 4. The presence or absence of the 
human tau gene in htau mice analyzed 
by Western blot. Using p-tau Ser396- 
specific antibodies, cortical p-tau Ser396 
was not found in non-carrier (NC) mice 
and while carrier (C) mice had Ser396 
protein present. Housekeeping protein 
GAPDH was re- probed on the same 
membrane. 
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Figure 5. Impaired memory in the carrier animals were seen when compared to 
the non-carrier group in the Morris water maze. Learning deficits were seen in 
the carriers at Day 2 of training and continued to have a longer escape latency 
compared to the non-carrier. Statistics were analyzed by one way ANOVA 
with Tukey- Kramer post hoc test (p < 0.05), control non-carrier n= 10, control 
carrier n= 10. 
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Figure 6. Administration of tolfenamic acid attenuates memory observed in 
the Morris water maze. "*" indicates significantly different from control, 
determined by one-way analysis of variance with Tukey- Kramer post hoc test 
to compare all the columns (*p < 0.05, **p < 0.01), obtained using GraphPad 
Instat 3 software. Control n= 10, 5 mg/kg = 9, 50 mg/kg = 10. 
  
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
0 1 2 3 4 5 6 7 8 
E
sc
a
p
e 
L
a
te
n
cy
 (
s)
 
Days 
Control Carrier 
TA 5 mg/kg 
TA 50 mg/kg 
** 
* 
* 
** 
 25 
 
      
 
Figure 7. Long-term memory assessment of htau mice in probe 
trials after dosing with tolfenamic acid. The time spent in 
correct quadrant after acquisition trial- training trials was 
measured (A) Probe Trial I (Day 24). (B) Probe Trial II (Day 
34). "*" indicates significantly different from the other groups 
measured by one way ANOVA with Tukey- Kramer post hoc 
test (p < 0.05) using GraphPad InStat3 software. Control non-
carrier n= 10, control carrier n= 10, 5 mg/kg = 9, 50 mg/kg = 
10. 
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Figure 8. Cortical tau levels after administration of 
tolfenamic acid. (A) Total tau protein levels measured 
by Western blot. (B) Quantitative total tau protein levels 
normalized to GAPDH levels. Values shown are for the 
mean + SEM, n= 4. "*" indicates significantly lower 
than the control determined by one way ANOVA (p = 
0.032) and p < 0.05 according to Holm- Sidak post-test. 
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Figure 9. Tau gene expression decreased with tolfenamic 
acid administration. Tau mRNA was measured in cortical 
tissue by real-time PCR (qPCR) with GAPDH as endogenous 
control. Values are shown as +SEM, control n= 4; 5 mg/kg 
TA n= 5; 50 mg/kg TA n= 5. 
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Figure 10. Levels of phosphorylated tau at Ser396 after 
dosing with tolfenamic acid. (A) p-tau Ser396 protein 
represented by Western blot. (B) Protein levels were 
quantified as protein-to-ratio of housekeeper GAPDH. 
Values shown are for the mean + SEM, n=4). 
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Figure 11. Phosphorylated levels of tau at site Thr231 
after tolfenamic acid administration. (A) p-tau Thr231 
protein levels determined by Western blot analysis. (B) 
Protein quantification was normalized to GAPDH protein 
levels. Values are shown for the mean + SEM, n= 4). "*" 
denotes statistically different from control measured by 
one-way ANOVA (p = 0.07) and p < 0.05 according to 
Holm- Sidak post-test. 
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Figure 12. Phosphorylated tau staining was reduced following 
treatment with tolfenamic acid.  Cell bodies, dendrites and axonal 
tracts in the frontal cortex and striatum were stained for p-tau Thr231 
in the control and 50 mg/kg tolfenamic acid group. 
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Table 1. Average weight of each treatment group 
over administration of either control corn oil or 
tolfenamic acid showed no serious change in 
weight or toxic effects of tolfenamic acid during 
the 34 days of dosing, followed by sacrifice on 
Day 35. 
Groups Day 1 (g) Day 35 (g) 
Control Carrier 36.58 34.90 
Control Non-carrier 30.73 30.39 
5 mg/kg TA 33.99 33.26 
50 mg/kg TA 34.75 33.97 
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